Caribou Biosciences, Inc. CRBU
1.24
(0.01)
(0.80%)
as of 25 Sep
- Market cap
- $134.0M
- P/E
- 0.0×
Follow CRBU
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
23.39 | 13.31 | 16.26 | 17.71 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.63) | (7.13) | (6.75) | (7.80) | |
P/B ratio |
1.53 | 1.22 | 1.79 | 1.81 | |
Price to Tangible BV |
1.53 | 1.22 | 1.79 | 1.81 | |
EV/Sales |
7.54 | 0.82 | 5.76 | 6.52 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.56) | (0.08) | (0.64) | (0.68) | |
EV/FCF |
(0.55) | (0.08) | (0.63) | (0.49) | |
Quick Ratio |
5.32 | 5.56 | 6.06 | 6.32 | |
Current Ratio |
5.54 | 5.71 | 6.22 | 6.49 | |
Net Debt/EBITDA |
5.08 | 4.99 | 4.54 | 4.54 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.05 | 0.05 | 0.06 | |
Operating CF/Net income |
0.91 | 0.79 | 1.08 | 0.94 | |
Capex/Depreciation |
(309.96) | 0.41 | (0.19) | 147.31 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,019.15% | 604.29% | 859.87% | 1,263.64% | |
Selling, General and Administrative Expense of Revenue |
418.43% | 217.69% | 336.50% | 526.75% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
133.35% | 69.47% | 98.33% | 165.24% | |
Graham Net Nets |
0.47 | 0.62 | 0.41 | 0.40 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(72.96%) | (100.00%) | (74.74%) | (61.36%) | |
Free Cash Flow Yield |
(58.76%) | (75.66%) | (55.80%) | (74.71%) | |
Revenue per Share |
0.02 | 0.04 | 0.03 | 0.01 | |
Operating CF per Share |
(0.27) | (0.22) | (0.28) | (0.23) | |
Capex per Share |
(1.32) | 0.00 | 0.00 | 0.85 | |
Free Cash Flow per Share |
(1.59) | (0.22) | (0.28) | 0.62 | |
Cash per Share |
1.58 | 1.49 | 1.23 | 1.11 | |
Shareholders Equity per Share |
1.52 | 1.31 | 1.06 | 0.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.52 | 1.31 | 1.06 | 0.97 | |
Free Cash Flow |
(147.93) | (20.61) | (27.06) | 62.80 | |
Working Capital |
127.45 | 119.82 | 102.71 | 98.62 | |
Capital Expenditures |
(122.74) | 0.22 | (0.07) | 85.59 | |
Net Current Asset Value |
102.37 | 92.04 | 75.40 | 71.92 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
55.84 | (0.05) | 0.03 | (57.10) | |
Net Profit Margin |
(1,253.32%) | (672.11%) | (1,046.52%) | (1,619.88%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.97 | 2.03 | 1.80 | 1.68 | |
Average Payables |
3.25 | 4.13 | 3.69 | 3.16 | |
Average Assets |
269.66 | 244.34 | 211.33 | 181.84 | |
Average Common Equity |
211.52 | 187.56 | 159.62 | 132.12 |
Columns are period end dates